Anna-Kathrine Fevre’s articles from aera are most popular:
- within Intellectual Property topic(s)
- with Senior Company Executives, HR and Inhouse Counsel
- in United States
- with readers working within the Chemicals industries
On 13 August, the UPC Court of Appeal held that a marketing authorisation alone is not enough, but once a health technology assessment (HTA), pricing and reimbursement are completed, imminent infringement may be established. Pharmaceutical companies must therefore monitor regulatory steps closely to act in time.
Read the full article by Anna-Kathrine Fevre here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]